ResMed Inc. 10-Q Summary: Period Ended December 31, 2009
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a leading developer and manufacturer of medical equipment for sleep-disordered breathing and respiratory disorders. The report covers the three and six-month periods ended December 31, 2009. The company operates manufacturing facilities in Australia, Singapore, France, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2009 | Six Months Ended Dec 31, 2009 |
|---|---|---|
| Net Revenues | $275.1 million | $522.1 million |
| Gross Profit | $164.2 million | $314.4 million |
| Gross Margin | 59.7% | 60.2% |
| Net Income | $46.0 million | $88.1 million |
| Diluted EPS | $0.60 | $1.15 |
| Cash and Cash Equivalents | $451.4 million (as of Dec 31, 2009) | |
| Total Debt | ||
| Working Capital | $687.0 million (as of Dec 31, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 23% ($52.2 million) for the quarter and 18% for the six-month period compared to the prior year. Growth was driven by increased unit sales of flow generators, masks, and accessories, as well as favorable foreign currency movements ($13.3 million impact in the quarter).
- Profitability: Net income rose 36% for the quarter and 42% for the six-month period. Gross margins improved to 59.7% (quarter) and 60.2% (six months) due to manufacturing cost savings and the depreciation of the Australian dollar against the U.S. dollar.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 20% for the quarter, primarily due to personnel increases and currency impacts. Research and development (R&D) expenses increased 28% for the quarter to support new product development.
- Acquisition: On October 1, 2009, the company acquired Laboratoires Narval SA for approximately EUR 8 million to expand its therapy offerings for mild obstructive sleep apnea.
Guidance, Outlook, and Risks
- Outlook: Management expects future SG&A expenses to remain between 30% and 31% of net revenue, and R&D expenses between 6% and 7% of net revenue. The company continues to invest in R&D and product enhancements, including the ApneaLink Plus and Swift FX mask.
- Liquidity: The company maintains strong liquidity with $451.4 million in cash. It has a $65 million revolving credit facility with $64.1 million outstanding and various syndicated term loans totaling approximately $145.1 million in long-term debt.
- Risks and Contingencies:
- Foreign Currency: Significant exposure to the Australian dollar, Euro, and British Pound. The company uses hedging instruments to manage this risk.
- Investment Liquidity: The company holds approximately $3.7 million in auction rate securities. While management believes the lack of liquidity is temporary, there is a risk these cannot be liquidated at par value before June 29, 2010.
- Legal: Ongoing litigation with the University of Sydney regarding intellectual property and a tax audit in Germany. Management does not expect these to have a material adverse effect.
Investor Verification Checklist
- Verify the sustainability of gross margin expansion given the volatility of the Australian dollar.
- Monitor the liquidity status of the $3.7 million auction rate securities and the company's ability to access these funds if needed before June 2010.
- Review the integration and revenue contribution of the Laboratoires Narval SA acquisition.
- Assess the impact of ongoing legal proceedings in Australia and Germany on future tax provisions or operational restrictions.
- Confirm the execution of the share repurchase program, which has 8.5 million shares remaining under the current authorization.